Marcum Bernstein & Pinchuk LLP ("MarcumBP"), a top-ranked provider of SEC audit, accounting and consulting services to Chinese companies listed in the U.S. capital markets, was a featured presenter at the inaugural China healthcare investor conference presented by Maxim Group and Haitong Securities in Shanghai on March 6 and 7, 2017.

The debut Healthcare Investor and Partnering Conference brought together executives of U.S. healthcare companies, Chinese institutional investors, and Chinese healthcare enterprises for two days of company presentations and networking. As a lead presenter, MarcumBP brought to the conference highly specialized experience in regulatory, operational, financial, clinical, assurance and tax services to the healthcare industry. Drew Bernstein, co-managing partner, addressed the conference on the subject of "U.S.-China Healthcare Partnerships: M&A, Partnering, and Sinofication.

"The Chinese healthcare market is on the verge of profound disruptions, driven by the intersection of demographics, income distribution, disease states, and technology," Mr. Bernstein said. "China is poised to become the largest pharmaceutical market in the world, with healthcare spending projected to reach $1.49 trillion by 2020 and an over-65 population of 348 million by 2050. These changes will have significant implications for cross-border M&A, partnership structures, and 'Sinofication' for multi-nationals looking to access the China market."

MarcumBP's dedicated China Healthcare Team provides assurance, tax, risk management, and cross-border M&A support to both Chinese and U.S. companies. An affiliate of Marcum LLP, one of the largest independent accounting and advisory firms in the United States, Marcum BP also has access to a deep bench of expertise in the Firm's national Healthcare Practice Group, including all aspects of corporate tax services, regulatory compliance and operational best practices.